J Child Adolesc Psychopharmacol. 2015 Jun;25(5):415-424.
Sikoglu EM1,2,3, Navarro AA1,2,3,4, Starr D2,3, Dvir Y2,3, Nwosu BU5, Czerniak SM1, Rogan RC1, Castro MC2,3, Edden RA6,7, Frazier JA2,3,5, Moore CM1,2,3,8.
1 Center for Comparative NeuroImaging, University of Massachusetts Medical School , Worcester, Massachusetts.
2 Child and Adolescent NeuroDevelopment Initiative, University of Massachusetts Medical School , Worcester, Massachusetts.
3 Department of Psychiatry, University of Massachusetts Medical School , Worcester, Massachusetts.
4 Office Médico-Pédagogique, Department of Psychiatry, University of Geneva School of Medicine , Geneva, Switzerland .
5 Department of Pediatrics, University of Massachusetts Medical School, Worcester , Massachusetts.
6 Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine , Baltimore, Maryland.
7 F.M. Kirby Research Center for Functional Brain Imaging, Kennedy Krieger Institute , Baltimore, Maryland.
8 Department of Radiology, University of Massachusetts Medical School , Worcester, Massachusetts.
We aimed to determine the effect of an open-label 8 week Vitamin D3 supplementation on manic symptoms, anterior cingulate cortex (ACC) glutamate, and γ-aminobutyric acid (GABA) in youth exhibiting symptoms of mania; that is, patients with bipolar spectrum disorders (BSD). We hypothesized that an 8 week Vitamin D3 supplementation would improve symptoms of mania, decrease ACC glutamate, and increase ACC GABA in BSD patients. Single time point metabolite levels were also evaluated in typically developing children (TD).
The BSD group included patients not only diagnosed with BD but also those exhibiting bipolar symptomology, including BD not otherwise specified (BD-NOS) and subthreshold mood ratings (Young Mania Rating Scale [YMRS] ≥8 and Clinical Global Impressions - Severity [CGI-S] ≥3). Inclusion criteria were: male or female participants, 6-17 years old. Sixteen youth with BSD exhibiting manic symptoms and 19 TD were included. BSD patients were asked to a take daily dose (2000 IU) of Vitamin D3 (for 8 weeks) as a supplement. Neuroimaging data were acquired in both groups at baseline, and also for the BSD group at the end of 8 week Vitamin D3 supplementation.
Baseline ACC GABA/creatine (Cr) was lower in BSD than in TD (F[1,31]=8.91, p=0.007). Following an 8 week Vitamin D3 supplementation, in BSD patients, there was a significant decrease in YMRS scores (t=-3.66, p=0.002, df=15) and Children's Depression Rating Scale (CDRS) scores (t=-2.93, p=0.01, df=15); and a significant increase in ACC GABA (t=3.18, p=0.007, df=14).
Following an 8 week open label trial with Vitamin D3,
BSD patients exhibited improvement in their mood symptoms in conjunction with their brain neurochemistry.
As has been seen with scores of other vitamin D studies, more than 2,000 IU of vitamin D would provide much more benefit
- Bipolar category listing has
15 items along with related searches
- 44X increase in Bipolar Disorder in youth in a decade – Sept 2007 many items
- Manic depressives (Bipolar I) have low vitamin D levels – Jan 2018
- Hypothesis: Some Mental Illness could be treated or prevented with vitamin D
Bipolar Spectrum Disorder decreased with 2,000 IU of vitamin D - June 2015
- Vitamin D supplementation in bipolar depression: A double blind placebo controlled trial Dec 2017
5,000IU Vitamin D3 po qday.(daily by mouth) VitD group levels increased to only 28 ng/ml. in 12 weeks
- Daily Mail article on Birth Month - June 2011 sample table follows
3381 visitors, last modified 30 Apr, 2021,